Literature DB >> 23891586

Modeling the dynamics of hepatitis C virus with combined antiviral drug therapy: interferon and ribavirin.

Sandip Banerjee1, Ram Keval, Sunita Gakkhar.   

Abstract

A mathematical modeling of hepatitis C virus (HCV) dynamics and antiviral therapy has been presented in this paper. The proposed model, which involves four coupled ordinary differential equations, describes the interaction of target cells (hepatocytes), infected cells, infectious virions and non-infectious virions. The model takes into consideration the addition of ribavirin to interferon therapy and explains the dynamics regarding a biphasic and triphasic decline of viral load in the model. A critical drug efficacy parameter has been defined and it is shown that for an efficacy above this critical value, HCV is eradicated whereas for efficacy lower this critical value, a new steady state for infectious virions is reached, which is lower than the previous steady state value.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Hepatitis C virus (HCV); Infected cells; Infectious virions; Interferon; Noninfectious virions; Ribavirin; Target cells

Mesh:

Substances:

Year:  2013        PMID: 23891586     DOI: 10.1016/j.mbs.2013.07.005

Source DB:  PubMed          Journal:  Math Biosci        ISSN: 0025-5564            Impact factor:   2.144


  3 in total

1.  The influence of vaccination on the control of JE with a standard incidence rate of mosquitoes, pigs and humans.

Authors:  Vinod Baniya; Ram Keval
Journal:  J Appl Math Comput       Date:  2020-06-09

2.  Effect of an antiviral drug control and its variable order fractional network in host COVID-19 kinetics.

Authors:  Bo Wang; Jayanta Mondal; Piu Samui; Amar Nath Chatterjee; Abdullahi Yusuf
Journal:  Eur Phys J Spec Top       Date:  2022-02-01       Impact factor: 2.891

Review 3.  Integrating mathematical models with experimental data to investigate the within-host dynamics of bacterial infections.

Authors:  Myrto Vlazaki; John Huber; Olivier Restif
Journal:  Pathog Dis       Date:  2019-11-01       Impact factor: 3.166

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.